Increased matrix metalloproteinases 2 and 9 and tissue inhibitor of matrix metalloproteinase 2 expression is associated with progression from vulvar intraepithelial neoplasia to invasive carcinoma

Acta Obstetricia et Gynecologica Scandinavica

Volumn 89, Issue 3, 2010, Pages 380-384

  Määttä, Milla ^a   Santala, Markku ^a   Soini, Ylermi ^a   Turpeenniemi Hujanen, Taina ^a   Talvensaari Mattila, Anne ^a  

^a UNIVERSITY OF OULU   (Finland)

Author keywords

Matrix metalloproteinases; Squamous cell vulvar carcinoma; Tissue inhibitors of matrix metalloproteinases; Vulvar intraepithelial neoplasia

Indexed keywords

GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER INVASION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; VULVA CANCER; VULVA CARCINOMA; VULVAR INTRAEPITHELIAL NEOPLASIA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; FEMALE; FINLAND; HUMANS; IMMUNOENZYME TECHNIQUES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TISSUE INHIBITOR OF METALLOPROTEINASE-2; VULVAR NEOPLASMS;

EID: 77749337518     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.3109/00016340903555990     Document Type: Article

References (26)

1. Fox H, Wells M. Recent advances in the pathology of the vulva. Histopathology. 2003;42:209-16.
2. Scurry J, Wilkinson EJ. Reviwev of terminology of precursors of vulvar squamous cell carcinoma. J Low Genit Trac Dis. 2006;10:161-9.
3. Rouzier R, Morice P, Haie-Meder C, Lhomme C, Avril MF, Duvillard P, Castaigne D. Prognostic significance of epithelial disorders adjacent to invasive vulvar carcinomas. Gyn Oncol. 2001;81:414-19.
4. Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T. Regulation of matrixmetalloproteins: an overview. Mol Cell Biochem. 2003;253:269-85.
5. Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 2000;72;19:6642-50.
6. Kerkela E, Saarialho-Kere U. Matri metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer. Exp Dermatol. 2003;12:109-25.
7. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: Biological activity and clinical implications. J Clin Oncol. 2000;18:1135-49.
8. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. Cancer 1993;71: 1260-70.
9. Jiang Y, Goldber ID, Shi E. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene. 2002;21:2245-52.
10. Bovo AC, Guerreiro da Silva ID, Takita L, Fochi J, Stavale J, Marks G, Lima GR. A comparative study of MMP-2 in vulvar neoplasms. Gyn Oncol. 2004;93:454-7.
11. Höyhtyä M, Fridman R, Komarck D, Porter-Jordan K, Stetler-Stevenson WG, Liotta LA, et al. Immunohistochemical localization of matrix metalloproteinase-2 and its spesific inhibitor TIMP-2 in neoplastic tissue with monoclonal antibodies. Int J Cancer. 1994;54:500-5.
12. Talvensaari A, Apaja-Sarkkinen M, Höyhtyä M, Westerlund A, Puistola U, Turpeenniemi-Hujanen T. Matrix metalloproteinase 2 immunoreactive protein appears early in cervical epithelial dedifferentiation. Gyn Oncol. 1999;72: 306-11.
13. Da Silva Cardeal LB, Brohem CA, Correa TC, Winnischofer SM, Nakano F, Boccardo E, et al. Higher expression and activity of metelloproteinases in human cervical carcinoma cell lines is associated with HPV precence. Biochem Cell Biol. 2006;84:713-19.
14. Asha Nair S, Karunagaran D, Nair MB, Sudhakaran PR. Changes in matrix metalloproteinases and their endogenous inhibitors during tumor progression in the uterine cervix. J Cancer Res Clin Oncol. 2003;129:123-31.
15. Brummer O, Böhmer G, Hollwitz B, Flemmig P, Petry KU, Kuhnle H. MMP-1 and MMP-2 in the cervix uteri in different steps of malignant transformationan immunohistochemical study. Gyn Oncol. 2002;84:222-7.
16. Gaiotto MA, Focchi J, Ribalta JL, Stavale JN, Baracat EC, Lima GR, Guerreiro da Silva ID: Comparative study of MMP-2 (matrix metalloproteinase-2) immune expression in normal uterine cervix, intraepithelial neoplasias and squamous cells cervical carcinoma. Am J Obstet Gynecol. 2004;190: 1278-82.
17. Nasr M, Ayyad SB, El-Lamie IK, Mikhail MY. Expression of matrix metalloproteinase-2 in preinvasive and invasive carcinoma of the uterine cervix. Eur J Gynecol Oncol. 2005;26:199-202.
18. Branca M, Ciotti M, Giorgi C, Santini D, Di Bonito L, Costa S, et al.; HPV-PathogenISS Study Group. Matrix metalloproteinase-2 (MMP-2) and its tissue inhibitor (TIMP-2) are prognostic factors in cervical cancer, related to invasive disease but not high-risk human papillomavirus (HPV) or virus persistance after treatment of CIN. Anticancer Res. 2006:1543-56.
19. Davidson B, Goldberg J, Kopolovic L, Lerner-Geva L, Gotlieb WH, Weis B, et al. Expression of matrix metalloproteinase-9 in squamous cell carcinoma of the uterine cervix-clicopathologic study using immunohistochemistry and mRNA in situ hybridization. Gyn Oncol. 1999;72:380-6.
20. Shimada T, Nakamura H, Yamashita K, Kawata R, Murakami Y, Fujimoto N, et al. Enhancd production and activation of progelatinases A mediated by membrane-type 1 matrix metalloproteinase in human oral squamous cell carcinoma: implications for lymph node metastasis. Clin Exp Metast. 2000:18:179-88.
21. De Vicente JC, Fresno MF, Villain L, Vega JA, Lopez Arranz JS. Immunoexpression and prognostic significance of TIMP-1 and -2 in oral squamous cell carcinoma. Oral Oncol. 2005:41;568-79.
22. Christopoulos TA, Papageorgakopoulos N, Ravazoula P, Masrtonikolis NS, Papados TA, Theocharis DA, et al. Expression of matrix metalloproteimases and their inhibitors in squamous cell laryngeal carcinoma. Oncol Rep. 2007;18:855-60.
23. Aglund K, Rauvala M, Puistola U, Angstrom T, Turpeenniemi-Hujanen T, Zackrisson B, et al. Gelatinases A and B (MMP-2 and MMP-9) in endometrial cancer-MMP-9 correlates to the grade and stage. Gyn Oncol. 2004;94:699-704.
24. Graesslin O, Cortez A, Fauvet R, Lorenzato M, Birembaut P, Darai E. Metalloproteinase-2, -7 and -9 and tissue inhibitor of metalloproteinase-1 and -2 expression in normal, hyperplastic and neoplastic endometrium: a clinical-pathological correlation study. Ann Oncol. 2006;17:637-45.
25. Honkavuori M, Talvensaari-Mattila A, Soini Y, Turpeenniemi-Hujanen T, Santala M. MMP-2 expression associates with CA 125 and clinical course in endometrial carcinoma. Gyn Oncol 2007;104:217-21.
26. Maatta M, Santala M, Soini Y, Talvensaari A, Turpeenniemi-Hujanen T. Matrix metalloproteinases 2 and 9 and their tissue inhibitors in low maliganat potential ovarian tumors. Tumor Biol. 2004;25:188-92.